OCS-02 (licaminlimab), an anti-TNFα eye drop candidate specifically designed to treat ocular inflammation, has the potential transform the treatment paradigm of DED with a precision medicine strategy. DED is a multifactorial disease in which ocular surface inflammation plays a central role in sustaining the pathological state 2.

OCS-02 positive results highlight its potential to transform the treatment paradigm of DED with a precision medicine strategy. RELIEF (Randomized Evaluation of Licaminlimab’s Efficacy and Safety for Dry Eye Disease) is a Phase 2b multi-center, randomized, double-masked, vehicle-controlled trial evaluating the efficacy and safety of ...

2022年3月30日 · Licaminlimab (Oculis SA, Lausanne, Switzerland), formerly known as OCS-02, LME636 and ESBA1622, is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFα.

2022年7月6日 · Topical ocular licaminlimab demonstrated statistically significant improvement in global ocular discomfort score compared to Vehicle in patients with severe DED, with good tolerability, no increase in IOP, and minimal systemic drug exposure.

2010年7月15日 · The Everpure EV9618-02 OCS2 is a quick-change water filter cartridge for Everpure QL series water filtration systems. Replaces older OCS water filter cartridges.

2022年8月24日 · 利卡明利单抗（OCS-02）为一种单链抗体（scFv），可结合并中和人体TNFα的活动，具有抗炎兼抗坏死的双重作用机制（MoA）。 有别于全长链单株抗体，单链抗体的分子较小，因此用作眼药滴剂时可以渗入眼表组织，有望成为首款获批治疗干眼病的外用生物制剂。 干眼病是一种多因素疾病，其中炎症能迅速发挥维持病理状态的核心作用。 有报告指，干眼病的全球流行率为11.59% ，即全球约有9亿名患者，单计美国目前就有1,600万至4,900万名干眼病患者。 …

07, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, announces First Patient First Visit (FPFV) in its Phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ innovative anti-TNFα biologic ...

OCS-02 is a potent topical ocular anti-TNFα antibody fragment. This randomized, active-controlled study (ClinicalTrials.gov NCT02482129, registered 6/26/2015, study start 7/17/2015) assessed OCS-02 efficacy and safety in acute anterior uveitis (AAU) patients.

OCS-02 (licaminlimab) is an anti-TNFα eye drop candidate developed with a single chain antibody fragment (scFv) technology specifically designed to treat ocular inflammatory diseases.

2022年4月8日 · OCS(online-course-script) 网课助手，官网 https://docs.ocsjs.com ，专注于帮助大学生从网课中释放出来 让自己的时间把握在自己的手中，拥有人性化的操作页面，流畅的步骤提示，支持 【超星学习通】 【知到智慧树】 【职教云】 【智慧职教】 【中国大学MOOC】 等网课 …